stockportfolio.pro
Stocks / IOVA vs OMCL
IOVA vs OMCL
Iovance Biotherapeutics, Inc. and Omnicell, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Iovance Biotherapeutics, Inc. (IOVA) | Omnicell, Inc. (OMCL) | |
|---|---|---|
| Market cap | $1.7B | $1.7B |
| Revenue (latest FY) | $263.50M | $1.18B |
| Net income (latest FY) | $-390.98M | $2.05M |
| Revenue growth (5y CAGR) | — | 5.8% |
| Net margin | -148.4% | 0.2% |
| Return on equity | -56.0% | 0.2% |
| P/E ratio | — | 87.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 9 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IOVA — free Open OMCL — freeFrequently asked questions
Which is bigger, IOVA or OMCL?
Omnicell, Inc. is larger by market capitalization — $1.7B versus $1.7B.
Which grows faster, IOVA or OMCL?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.